Media coverage
117
Media coverage
Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet Drugs.com Country/Territory United States Date 8/04/24 URL https://www.drugs.com/clinical_trials/linvoseltamab-pivotal-data-presented-aacr-reinforce-response-rate-deepens-over-time-patients-21428.html Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented At AACR Reinforce High Response Rate That Deepens Over Time In Patients With Heavily Pre-Treated Multiple Myeloma Media name/outlet MENAFN -Press Releases (English) Country/Territory Jordan Date 7/04/24 Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet Street Insider Country/Territory United States Date 7/04/24 URL https://www.streetinsider.com/Press+Releases/Linvoseltamab+Pivotal+Data+Presented+at+AACR+Reinforce+High+Response+Rate+that+Deepens+Over+Time+in+Patients+with+Heavily+Pre-Treated+Multiple+Myeloma/23036680.html Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet BioSpace Country/Territory United States Date 7/04/24 URL https://www.biospace.com/article/releases/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma/?s=85 Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet InvestorsObserver Country/Territory United States Date 7/04/24 URL https://www.investorsobserver.com/news/qm-pr/8705634665770988 Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet Yahoo! Finance Country/Territory United States Date 7/04/24 URL https://finance.yahoo.com/news/linvoseltamab-pivotal-data-presented-aacr-200000612.html Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet ADVFN UK Country/Territory United Kingdom Date 7/04/24 URL https://uk.advfn.com/stock-market/NASDAQ/REGN/share-news/Linvoseltamab-Pivotal-Data-Presented-at-AACR-Reinf/93615037 Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet Big Country Country/Territory United States Date 7/04/24 URL https://www.bigcountryhomepage.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet ADVFN US Country/Territory United States Date 7/04/24 URL https://www.advfn.com/stock-market/NASDAQ/REGN/stock-news/93615037/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-d Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet Stockwatch Country/Territory Canada Date 7/04/24 URL www.stockwatch.com/News/Item/U-z9085664-U!REGN-20240407/U/REGN Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet Crwe World Country/Territory United States Date 7/04/24 URL crweworld.com/article/news-provided-by-globenewswire/3352193/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet GlobeNewswire Country/Territory United States Date 7/04/24 URL https://www.globenewswire.com/news-release/2024/04/07/2858843/0/en/Linvoseltamab-Pivotal-Data-Presented-at-AACR-Reinforce-High-Response-Rate-that-Deepens-Over-Time-in-Patients-with-Heavily-Pre-Treated-Multiple-Myeloma.html Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma; Regulatory applications for linvoseltamab currently under review by the U.S. Food and Drug Administrati Media name/outlet GlobeNewswire Country/Territory United States Date 7/04/24 Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet Fox40 KTXL Country/Territory United States Date 7/04/24 URL https://fox40.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet KSNT TV Country/Territory United States Date 7/04/24 URL https://www.ksnt.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet FOX 59 Country/Territory United States Date 7/04/24 URL https://fox59.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet CW33 NewsFix Country/Territory United States Date 7/04/24 URL https://cw33.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet ConchoValleyHomepage.com Country/Territory United States Date 7/04/24 URL https://www.conchovalleyhomepage.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet MyPanhandle.com Country/Territory United States Date 7/04/24 URL https://www.mypanhandle.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet WOWK Country/Territory United States Date 7/04/24 URL https://www.wowktv.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet WYOU Country/Territory United States Date 7/04/24 URL https://www.pahomepage.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet WTVW FOX 7 Country/Territory United States Date 7/04/24 URL https://www.tristatehomepage.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet INFORMNNY.com Country/Territory United States Date 7/04/24 URL https://www.informnny.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet WSAV Country/Territory Georgia Date 7/04/24 URL https://www.wsav.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet KGET Country/Territory United States Date 7/04/24 URL https://www.kget.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet WBOY Country/Territory United States Date 7/04/24 URL https://www.wboy.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet WCBD Country/Territory United States Date 7/04/24 URL https://www.counton2.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet NBC4 Columbus Country/Territory United States Date 7/04/24 URL https://www.nbc4i.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet WBTW News13 Country/Territory United States Date 7/04/24 URL https://www.wbtw.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet FOX 31 News KDVR Country/Territory United States Date 7/04/24 URL https://kdvr.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet LocalSRY.com Country/Territory United States Date 7/04/24 URL https://www.localsyr.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet KTSM.com Country/Territory United States Date 7/04/24 URL https://www.ktsm.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet WRIC TV Country/Territory United States Date 7/04/24 URL https://www.wric.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet OzarksFirst.com Country/Territory United States Date 7/04/24 URL https://www.ozarksfirst.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet WWLP.com Country/Territory United States Date 7/04/24 URL https://www.wwlp.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet KHON 2 Country/Territory United States Date 7/04/24 URL https://www.khon2.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet Texomashomepage.com Country/Territory United States Date 7/04/24 URL https://www.texomashomepage.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet CBS4Indy Country/Territory United States Date 7/04/24 URL https://cbs4indy.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet WETM 18 Country/Territory United States Date 7/04/24 URL https://www.mytwintiers.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet KELOLAND TV Country/Territory United States Date 7/04/24 URL https://www.keloland.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet WPRI Country/Territory United States Date 7/04/24 URL https://www.wpri.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet KXNet.com Country/Territory United States Date 7/04/24 URL https://www.kxnet.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet KRQE Country/Territory United States Date 7/04/24 URL https://www.krqe.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet WDHN Country/Territory United States Date 7/04/24 URL https://www.wdhn.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet CNYHomepage.com Country/Territory United States Date 7/04/24 URL https://www.cnyhomepage.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet MyHighPlains.com Country/Territory United States Date 7/04/24 URL https://www.myhighplains.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet WRBL-TV Country/Territory Georgia Date 7/04/24 URL https://www.wrbl.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet KNWA Country/Territory United States Date 7/04/24 URL https://www.nwahomepage.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet WeAreGreenBay.com Country/Territory United States Date 7/04/24 URL https://www.wearegreenbay.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet WFXRTV.com Country/Territory United States Date 7/04/24 URL https://www.wfxrtv.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet WJHL.com Country/Territory United States Date 7/04/24 URL https://www.wjhl.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet FOX8 WGHP Country/Territory United States Date 7/04/24 URL https://myfox8.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet WLNS Country/Territory United States Date 7/04/24 URL https://www.wlns.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet Kark.com Country/Territory United States Date 7/04/24 URL https://www.kark.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet MyStateLine.com Country/Territory United States Date 7/04/24 URL https://www.mystateline.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet WNTZ Country/Territory United States Date 7/04/24 URL https://www.cenlanow.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet KLFY Country/Territory United States Date 7/04/24 URL https://www.klfy.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet WNCT Country/Territory United States Date 7/04/24 URL https://www.wnct.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet WREG Country/Territory United States Date 7/04/24 URL https://wreg.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet KTLA Country/Territory United States Date 7/04/24 URL https://ktla.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet Fox8 Country/Territory United States Date 7/04/24 URL https://fox8.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet WJET Country/Territory United States Date 7/04/24 URL https://www.yourerie.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet WKRG Country/Territory United States Date 7/04/24 URL https://www.wkrg.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet Fox 16 Country/Territory United States Date 7/04/24 URL https://www.fox16.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet ABC 4 Country/Territory United States Date 7/04/24 URL https://www.abc4.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet WIProud.com Country/Territory United States Date 7/04/24 URL https://www.wiproud.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet WJBF-TV Country/Territory Georgia Date 7/04/24 URL https://www.wjbf.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet WPHL-TV Country/Territory United States Date 7/04/24 URL https://phl17.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet 8 News Now Country/Territory United States Date 7/04/24 URL https://www.8newsnow.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet Binghamton Homepage Country/Territory United States Date 7/04/24 URL https://www.binghamtonhomepage.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet WVNS Country/Territory United States Date 7/04/24 URL https://www.wvnstv.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet WTen.com Country/Territory United States Date 7/04/24 URL https://www.news10.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet ABC 27 Country/Territory United States Date 7/04/24 URL https://www.abc27.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet WHNT-TV Country/Territory United States Date 7/04/24 URL https://whnt.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet WJTV.com Country/Territory United States Date 7/04/24 URL https://www.wjtv.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet FOX21News.com Country/Territory United States Date 7/04/24 URL https://www.fox21news.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet KSN Country/Territory United States Date 7/04/24 URL https://www.ksn.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet WTRF Country/Territory United States Date 7/04/24 URL https://www.wtrf.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet WDTN Country/Territory United States Date 7/04/24 URL https://www.wdtn.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet WIAT TV Country/Territory United States Date 7/04/24 URL https://www.cbs42.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet WKBN 27 First News Country/Territory United States Date 7/04/24 URL https://www.wkbn.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet FOX5 San Diego Country/Territory United States Date 7/04/24 URL https://fox5sandiego.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet WYTV News Country/Territory United States Date 7/04/24 URL https://www.wytv.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet WGNO Country/Territory United States Date 7/04/24 URL https://wgno.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet WSPA.com Country/Territory United States Date 7/04/24 URL https://www.wspa.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet KFOR.com Country/Territory United States Date 7/04/24 URL https://kfor.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet KODE TV Country/Territory United States Date 7/04/24 URL https://www.fourstateshomepage.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet Fox 4 WDAF TV Country/Territory United States Date 7/04/24 URL https://fox4kc.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet YOUR BASIN Country/Territory United States Date 7/04/24 URL https://www.yourbasin.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet WCIA.com Country/Territory United States Date 7/04/24 URL https://www.wcia.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet WesternSlopeNow.com Country/Territory United States Date 7/04/24 URL https://www.westernslopenow.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet Wavy Country/Territory United States Date 7/04/24 URL https://www.wavy.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet YourCentralValley.com Country/Territory United States Date 7/04/24 URL https://www.yourcentralvalley.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet My Champlain Valley Country/Territory United States Date 7/04/24 URL https://www.mychamplainvalley.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet Rochesterfirst.com Country/Territory United States Date 7/04/24 URL https://www.rochesterfirst.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet WANE-TV Country/Territory United States Date 7/04/24 URL https://www.wane.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet Myarklamiss.com Country/Territory United States Date 7/04/24 URL https://www.myarklamiss.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet WTWO Country/Territory United States Date 7/04/24 URL https://www.mywabashvalley.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet Valleycentral.com Country/Territory United States Date 7/04/24 URL https://www.valleycentral.com/business/press-releases/globenewswire/9085664/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Media name/outlet L' Observateur Country/Territory United States Date 7/04/24 URL https://smb.lobservateur.com/article/Linvoseltamab-Pivotal-Data-Presented-at-AACR-Reinforce-High-Response-Rate-that-Deepens-Over-Time-in-Patients-with-Heavily-Pre-Treated-Multiple-Myeloma?storyId=6612fc190f3f3147fb6417be Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Media name/outlet MillisMedway - Local Town Pages Country/Territory United States Date 7/04/24 URL https://pr.millismedwaynews.com/article/Linvoseltamab-Pivotal-Data-Presented-at-AACR-Reinforce-High-Response-Rate-that-Deepens-Over-Time-in-Patients-with-Heavily-Pre-Treated-Multiple-Myeloma?storyId=6612fc190f3f3147fb6417be Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Media name/outlet Luverne Journal Country/Territory United States Date 7/04/24 URL https://smb.luvernejournal.com/article/Linvoseltamab-Pivotal-Data-Presented-at-AACR-Reinforce-High-Response-Rate-that-Deepens-Over-Time-in-Patients-with-Heavily-Pre-Treated-Multiple-Myeloma?storyId=6612fc190f3f3147fb6417be Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Media name/outlet Kenbridge Victoria Dispatch Country/Territory United States Date 7/04/24 URL https://smb.kenbridgevictoriadispatch.com/article/Linvoseltamab-Pivotal-Data-Presented-at-AACR-Reinforce-High-Response-Rate-that-Deepens-Over-Time-in-Patients-with-Heavily-Pre-Treated-Multiple-Myeloma?storyId=6612fc190f3f3147fb6417be Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Media name/outlet BluegrassLive.com Country/Territory United States Date 7/04/24 URL https://smb.bluegrasslive.com/article/Linvoseltamab-Pivotal-Data-Presented-at-AACR-Reinforce-High-Response-Rate-that-Deepens-Over-Time-in-Patients-with-Heavily-Pre-Treated-Multiple-Myeloma?storyId=6612fc190f3f3147fb6417be Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Media name/outlet TheTidewaterNews.com Country/Territory United States Date 7/04/24 URL https://smb.thetidewaternews.com/article/Linvoseltamab-Pivotal-Data-Presented-at-AACR-Reinforce-High-Response-Rate-that-Deepens-Over-Time-in-Patients-with-Heavily-Pre-Treated-Multiple-Myeloma?storyId=6612fc190f3f3147fb6417be Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Media name/outlet Times of San Diego Country/Territory United States Date 7/04/24 URL https://pr.timesofsandiego.com/article/Linvoseltamab-Pivotal-Data-Presented-at-AACR-Reinforce-High-Response-Rate-that-Deepens-Over-Time-in-Patients-with-Heavily-Pre-Treated-Multiple-Myeloma?storyId=6612fc190f3f3147fb6417be Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Media name/outlet Leesville Leader Country/Territory United States Date 7/04/24 URL https://smb.theleesvilleleader.com/article/Linvoseltamab-Pivotal-Data-Presented-at-AACR-Reinforce-High-Response-Rate-that-Deepens-Over-Time-in-Patients-with-Heavily-Pre-Treated-Multiple-Myeloma?storyId=6612fc190f3f3147fb6417be Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Media name/outlet Holliston - Local Town Pages Country/Territory United States Date 7/04/24 URL https://pr.hollistontownnews.com/article/Linvoseltamab-Pivotal-Data-Presented-at-AACR-Reinforce-High-Response-Rate-that-Deepens-Over-Time-in-Patients-with-Heavily-Pre-Treated-Multiple-Myeloma?storyId=6612fc190f3f3147fb6417be Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated... Media name/outlet Smithfield Times Country/Territory United States Date 7/04/24 URL https://smb.smithfieldtimes.com/article/Linvoseltamab-Pivotal-Data-Presented-at-AACR-Reinforce-High-Response-Rate-that-Deepens-Over-Time-in-Patients-with-Heavily-Pre-Treated-Multiple-Myeloma?storyId=6612fc190f3f3147fb6417be Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Media name/outlet LaGrange Daily News Country/Territory Georgia Date 7/04/24 URL https://smb.lagrangenews.com/article/Linvoseltamab-Pivotal-Data-Presented-at-AACR-Reinforce-High-Response-Rate-that-Deepens-Over-Time-in-Patients-with-Heavily-Pre-Treated-Multiple-Myeloma?storyId=6612fc190f3f3147fb6417be Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Media name/outlet Port Arthur News Country/Territory United States Date 7/04/24 URL https://smb.panews.com/article/Linvoseltamab-Pivotal-Data-Presented-at-AACR-Reinforce-High-Response-Rate-that-Deepens-Over-Time-in-Patients-with-Heavily-Pre-Treated-Multiple-Myeloma?storyId=6612fc190f3f3147fb6417be Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Media name/outlet Jessamine Journal Country/Territory United States Date 7/04/24 URL https://smb.jessaminejournal.com/article/Linvoseltamab-Pivotal-Data-Presented-at-AACR-Reinforce-High-Response-Rate-that-Deepens-Over-Time-in-Patients-with-Heavily-Pre-Treated-Multiple-Myeloma?storyId=6612fc190f3f3147fb6417be Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Media name/outlet Tryon Daily Bulletin Country/Territory United States Date 7/04/24 URL https://smb.tryondailybulletin.com/article/Linvoseltamab-Pivotal-Data-Presented-at-AACR-Reinforce-High-Response-Rate-that-Deepens-Over-Time-in-Patients-with-Heavily-Pre-Treated-Multiple-Myeloma?storyId=6612fc190f3f3147fb6417be Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Media name/outlet Suffolk News Herald Country/Territory United States Date 7/04/24 URL https://smb.suffolknewsherald.com/article/Linvoseltamab-Pivotal-Data-Presented-at-AACR-Reinforce-High-Response-Rate-that-Deepens-Over-Time-in-Patients-with-Heavily-Pre-Treated-Multiple-Myeloma?storyId=6612fc190f3f3147fb6417be Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Media name/outlet Elizabethton.com Country/Territory United States Date 7/04/24 URL https://smb.elizabethton.com/article/Linvoseltamab-Pivotal-Data-Presented-at-AACR-Reinforce-High-Response-Rate-that-Deepens-Over-Time-in-Patients-with-Heavily-Pre-Treated-Multiple-Myeloma?storyId=6612fc190f3f3147fb6417be Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Media name/outlet Winchester Sun Country/Territory United States Date 7/04/24 URL https://smb.winchestersun.com/article/Linvoseltamab-Pivotal-Data-Presented-at-AACR-Reinforce-High-Response-Rate-that-Deepens-Over-Time-in-Patients-with-Heavily-Pre-Treated-Multiple-Myeloma?storyId=6612fc190f3f3147fb6417be Persons Sundar Jagannath Title Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Media name/outlet Regeneron Country/Territory United States Date 7/04/24 URL https://newsroom.regeneron.com/news-releases/news-release-details/linvoseltamab-pivotal-data-presented-aacr-reinforce-high Persons Sundar Jagannath